Amgen posts results for terminated acapatamab mCRPC trial; updates MARITIME-PEN and AMG 691 recordsNov 13Weekly roundup, 6 itemsacapatamabAMG-691Updated
New daratumumab Phase 2 results posted in stage 3B AL amyloidosis; AFT-19 results still standingNov 13Weekly roundup, 5 itemsapalutamidedaratumumabUpdated
Novartis updates pediatric asciminib CML trial; opens new schizophrenia drug studyNov 13Weekly roundup, 6 itemsasciminibinotuzumab ozogamicin
FDA approves capivasertib combo for PTEN-deficient prostate cancerNov 6Regulatory decisionAstraZenecacapivasertib
Lilly posts galunisertib PFS results in prostate cancer; registers new bimagrumab HFpEF trialNov 6Weekly roundup, 7 itemsbimagrumabEli LillyUpdated
Novartis registers two Phase I trials: TRB191 in SCLC and XEP527 in schizophreniaNov 6Weekly roundup, 10 itemsArdtartemether and lumefantrine
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
FDA approves talazoparib plus enzalutamide for a new prostate cancer populationOct 26Regulatory decisionenzalutamidePfizer
Pfizer registers four studies: elranatamab, berobenatide, tilrekimig, and completed etrasimod trialOct 23Weekly roundup, 14 itemsabrocitinibatirmociclibUpdated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
Pfizer registers real-world observational study of marstacimab in hemophilia A and B patientsOct 9Weekly roundup, 8 itemsabrocitinibcyclophosphamide
Vir Biotechnology says FDA grants Fast Track to VIR-5500 for prostate cancerOct 8Regulatory milestoneAstellas PharmaVir Biotechnology, Inc.
Kairos Pharma reports positive interim PFS data for ENV-105 in prostate cancer trialOct 6Clinical readoutKairos Pharma, LTD.
AstraZeneca posts CAPItello-281 results in PTEN-deficient prostate cancer; registers AZD4954 Phase 1Sep 10Weekly roundup, 2 itemsAstraZenecaAZD4954
FDA approves ZAVZPRET label update; Pfizer registers RSVpreF and prostate cancer studiesAug 21Weekly roundup, 7 itemsBioNTech SEPenbraya
Vir reports Week 96 SOLSTICE data, ECLIPSE program fully enrolled, VIR-5500 expansion underwayAug 5Quarterly updateVir Biotechnology, Inc.VIR-5500
ORIC Pharmaceuticals starts Phase 3 Himalayas-1 trial, adds Bayer supply dealAug 3Quarterly updateORIC Pharmaceuticals
New Phase 2a trial registered for Amgen's xaluritamig after lutetium-177 therapyJul 30Trial updateAmgenxaluritamig
ORIC Pharmaceuticals registers Phase 3 Himalayas-1 trial for rinzimetostat in mCRPCJul 23Trial updateBayerdarolutamide
Kairos Pharma signs research agreement with Bayer to test ENV-105 with XOFIGO in prostate cancerJul 22Clinical readoutKairos Pharma, LTD.radium ra 223 dichloride
AstraZeneca posts PASSAGE Phase 4 tezepelumab results; registers new prostate, lung, and NF2 trialsJul 17Weekly roundup, 6 itemsAstraZenecaosimertinib
Telix and FDA align on ProstACT Global Phase 3 protocol, IND amendment pendingJul 2Clinical readoutTelix Pharmaceuticals Ltd
AstraZeneca posts Phase 3 LOGOS, KALOS asthma results; updates Soliris labelJul 2Weekly roundup, 5 itemsAstraZenecaAZD4045